290 related articles for article (PubMed ID: 9271488)
1. Biomedical research and insider trading.
Ferguson JR
N Engl J Med; 1997 Aug; 337(9):631-4. PubMed ID: 9271488
[No Abstract] [Full Text] [Related]
2. Clinical trial results, physicians, and insider trading.
Prentice RA
J Leg Med; 1999 Jun; 20(2):195-222. PubMed ID: 10407617
[No Abstract] [Full Text] [Related]
3. Physicians and Insider Trading.
Kesselheim AS; Sinha MS; Joffe S
JAMA Intern Med; 2015 Dec; 175(12):1955-9. PubMed ID: 26457747
[TBL] [Abstract][Full Text] [Related]
4. Fraud in scientific research: the prosecutor's approach.
Willcox BL
Account Res; 1992; 2(2):139-51. PubMed ID: 16144093
[No Abstract] [Full Text] [Related]
5. Inappropriate publication of trial results and potential for allegations of illegal share dealing.
Freestone DS; Mitchell H
BMJ; 1993 Apr; 306(6885):1112-4. PubMed ID: 8495159
[TBL] [Abstract][Full Text] [Related]
6. The clinical trial research participant as an inside trader: a legal and policy analysis.
Horwich A
J Health Law; 2006; 39(1):77-116. PubMed ID: 16761384
[TBL] [Abstract][Full Text] [Related]
7. Justices expand rights to experiment with patented drugs.
Pollack A
N Y Times Web; 2005 Jun; ():C1, C8. PubMed ID: 15966121
[No Abstract] [Full Text] [Related]
8. Wall Street and clinical trials.
Steinbrook R
N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
[No Abstract] [Full Text] [Related]
9. Uneasy alliance--clinical investigators and the pharmaceutical industry.
Bodenheimer T
N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196
[No Abstract] [Full Text] [Related]
10. SEC going after insider trading based on medical research results. Securities Exchange Commission.
Skolnick AA
JAMA; 1998 Jul; 280(1):10-1. PubMed ID: 9660347
[No Abstract] [Full Text] [Related]
11. Individual researcher liability for clinical research on humans.
Miller RK
J Biolaw Bus; 2003; 6(2):8-16. PubMed ID: 14682365
[TBL] [Abstract][Full Text] [Related]
12. Judgment day for NCFE. Defense cites sluggish government reimbursement.
Becker C
Mod Healthc; 2008 Feb; 38(6):10. PubMed ID: 18389583
[No Abstract] [Full Text] [Related]
13. Proprietary rights and the norms of science in biotechnology research.
Eisenberg RS
Yale Law J; 1987 Dec; 97(2):177-231. PubMed ID: 11660398
[No Abstract] [Full Text] [Related]
14. Disclosure of adverse clinical trial results--should legal immunity be granted to drug companies?
Vernillo A
Am J Bioeth; 2009 Aug; 9(8):45-7. PubMed ID: 19998162
[No Abstract] [Full Text] [Related]
15. Researcher said his colleague should have revealed possible conflicts of interest.
Maloney DM
Hum Res Rep; 2005 Jan; 20(1):8. PubMed ID: 15810184
[No Abstract] [Full Text] [Related]
16. Murky water. IRS probes firm doing loan pools for hospital groups.
Jaklevic MC
Mod Healthc; 2002 Feb; 32(5):8-9. PubMed ID: 11859823
[No Abstract] [Full Text] [Related]
17. Managing physician financial conflicts of interest in clinical trials conducted in the private practice setting.
Williams KM
Food Drug Law J; 2004; 59(1):45-77. PubMed ID: 15190925
[No Abstract] [Full Text] [Related]
18. The report of the committee of inquiry on the case involving Dr. Nancy Olivieri: a fiduciary law perspective.
Litman M; Sheremeta L
Health Law Rev; 2002; 10(2):3-13. PubMed ID: 15739307
[No Abstract] [Full Text] [Related]
19. More gold and more fleece: improving the legal sanctions against medical research fraud.
O'Reilly JT
Adm Law Rev; 1990; 42(3):393-422. PubMed ID: 15991411
[No Abstract] [Full Text] [Related]
20. SEC slaps another researcher for insider trading. Securities and Exchange Commission.
Skolnick AA
JAMA; 1998 Jul; 280(2):124. PubMed ID: 9669773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
